CLINICAL TRIALS PROFILE FOR BIFEPRUNOX
✉ Email this page to a colleague
Clinical Trials for Bifeprunox
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00134459 ↗ | Study Evaluating Bifeprunox in Bipolar Depression | Completed | Solvay Pharmaceuticals | Phase 3 | The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder. |
| NCT00134459 ↗ | Study Evaluating Bifeprunox in Bipolar Depression | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | The purpose of the study is to investigate whether eight weeks of treatment with flexible doses of bifeprunox is superior to treatment with placebo in depressed patients with bipolar disorder. |
| NCT00139906 ↗ | Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia | Completed | H. Lundbeck A/S | Phase 2 | This study is to assess the safety and tolerability of a five-day titration schedule (using twice daily dosing for the first three days) to achieve the highest proposed dose of 40 mg daily. The study duration is two months. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Bifeprunox
Condition Name
Clinical Trial Locations for Bifeprunox
Trials by Country
Clinical Trial Progress for Bifeprunox
Clinical Trial Phase
Clinical Trial Sponsors for Bifeprunox
Sponsor Name
